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Abstract
We aimed to investigate the effects of fish oil (FO) supplementation to pregnant women on the maternal and fetal fatty acid profile in
plasma and erythrocyte phospholipids (PL) and to identify the best compartment for the assessment of fatty acid status. A multi-centre,
double-blind, controlled trial was conducted. Healthy pregnant women from three European centres were randomly assigned to receive
from week 20 of gestation until delivery a daily dietary supplement with either FO (500 mg DHA þ 150 mg EPA), 400mg 5-methyltetrahy-
drofolate, both or placebo. Fatty acids in plasma and erythrocyte PL were determined in maternal blood (week 20, week 30 of pregnancy
and delivery) and in cord blood (delivery). FO supplementation increased DHA levels in maternal and cord plasma and erythrocyte PL.
Higher percentage changes were observed in erythrocyte PL than in plasma PL. There were significant correlations between plasma
and erythrocyte fatty acid levels in maternal and cord blood. Significant correlations between maternal and cord fatty acid levels at delivery
in plasma and erythrocytes were also observed; however, correlation coefficients were higher for erythrocyte phophatidylethanolamine.
FO supplementation increases maternal and fetal DHA status. Both plasma and erythrocytes appear to be suitable to evaluate the fatty
acid status of mothers but erythrocytes seem to be a more reliable marker in neonates.
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Fetal metabolism and development depend on nutrients cross-
ing the placenta and, therefore, on maternal nutritional status
and diet during pregnancy. The essential fatty acids and their
derivatives, long-chain PUFA (LC-PUFA), are essential constitu-
ents of membranes, especially in the brain and retina(1), and
must be provided to the fetus.
Given the importance of LC-PUFA in fetal development, in
recent years, growing interest has been given to maternal
fatty acid status. It is well known from interventional studies
that LC-PUFA supplementation to pregnant women signifi-
cantly increases LC-PUFA concentrations in both plasma and
erythrocyte phospholipids (PL) in the mother as well as in
the fetus(2–7). Few studies have assessed the effects of
supplementation on plasma and erythrocyte PL in the same
population(8,9). It is generally accepted that LC-PUFA in
plasma PL reflect tissue LC-PUFA status. Recent discussion
has centred on whether erythrocyte membrane PL might be
preferred to assess fatty acid status(10,11). In addition, a positive
correlation between folate and DHA levels has been reported
in human subjects(12). Although the detailed mechanism
remains unclear, the effect of folate supplementation on fatty
acid status might be attributable to the increased methionine
availability present after supplementation, which stimulates
the metabolism of essential fatty acids(13,14).
The present study was performed to investigate the effects
of supplementation with fish oil (FO) and/or 5-methyltetra-
hydrofolate (5-MTHF) from week 20 of gestation until delivery
on the fatty acid profile of plasma and erythrocyte PL of
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pregnant women during the course of pregnancy and fetal
LC-PUFA status. We also aimed to elucidate which is the best
compartment for the assessment of the fatty acid status of
pregnant women and their neonates.
Methods
Study design
Information regarding study design, recruitment, inclusion cri-
teria, dietary intervention, and collection of data and biological
material has been reported elsewhere(15). Briefly, a multi-
centre, randomised, double-blind controlled trial was con-
ducted. A total of 315 healthy pregnant women were recruited
before gestation week 20 at three different European centres
(Ludwig Maximilians University, Munich (Germany), the
University of Granada (Spain) and the University of Pecs
(Hungary)). Women who consumed FO supplements since
the beginning of pregnancy or vitamin B12 or folate sup-
plements after gestation week 16 were excluded from the
study. They were randomly assigned to four different groups
and received daily a dietary supplement, from gestation week
20 until delivery, consisting of FO (500 mg DHA þ 150 mg
EPA; Pronova Biocare), 400mg 5-MTHF (BASF), both or pla-
cebo together with vitamins and minerals in amounts meeting
the recommended intakes during the second half of pregnancy
for European women. The mothers were physically examined
at the 20th and 30th week of gestation and data on the course
of pregnancy and dietary intake were collected by means of
standardised questionnaires. At delivery, information about
delivery and data on the newborn were collected. At the 20th
and 30th week of gestation, 10 ml of maternal venous blood
were collected into EDTA, and at delivery, 12 ml of maternal
venous blood as well as 12 ml of venous cord blood were
collected. The main outcome variables were fatty acid relative
concentrations (wt%) in plasma and erythrocyte membrane
PL of cord and maternal blood.
The study protocol was approved by the Medical Ethics
Committees of all centres participating in the study. Written
informed consent was obtained from all participants. The pre-
sent trial was registered at www.clinicaltrials.gov (registration
no. NCT01180933).
Biochemical analyses
Sample collection procedure. At the 20th week (before sup-
plementations) and at the 30th week of gestation, 10 ml of
maternal blood were collected into EDTA-containing tubes
by venepuncture after an overnight fast. At delivery, 12 ml of
maternal blood were obtained as described for the samples
at the 20th and 30th week of pregnancy. Further, 12 ml of
placental venous cord blood samples were collected into
EDTA-containing tubes at delivery after clamping of the umbi-
lical cord and before parturition of the placenta by puncture
and aspiration from a long cord segment. Blood was centri-
fuged at 3500 rpm for 10 min at room temperature within
2 h. Plasma samples were frozen in liquid N2 at 21968C in
100 and 200ml aliquots and stored at 2808C until fatty acid
analyses. Blood cells were washed three times in isotonic
NaCl solution. The last sediment was haemolysed in 1 ml of
distilled water for 20 min at room temperature, and then 2 ml
ice-cold isopropylic alcohol with 0·5 % butylated hydroxyto-
luene were added as an antioxidant and the samples were
stored at 2808C until further analyses.
Analyses of fatty acids in maternal and umbilical cord
plasma and erythrocyte phospholipids. Total lipid extraction
from plasma was performed according to the method of
Kolarovic & Fournier(16). Briefly, 0·5 ml plasma plus 0·5 ml
water were vortexed for 30 s with 100ml of internal standard
(0·857 g diheptadecanoyl phosphatidylcholine (PC)/l dis-
solved in chloroform). Then, lipids were extracted four
times, initially with n-hexane–2-propanolol (3:2, v/v) contain-
ing 25 mg/l of butylated hydroxytoluene as an antioxidant and
then three times with pure hexane. The pooled extracts were
dried under vacuum and dissolved in 200ml hexane–methyl-
tert-butyl-diethyl ether–acetic acid (100:3:0·3, by vol.) and PL
were isolated by liquid chromatography using aminopropyl
columns (Sep Pak Cartridges; Waters) as described by
Agren et al.(17).
Lipids from erythrocytes were extracted by adding 3 ml
chloroform and two internal standards (phosphatidylethanola-
mine (PE)-heptadecanoate and PC-pentadecanoate esters dis-
solved in methanol). The mixture was shaken on a vortex and
the lower layer was aspirated and evaporated under a N2
stream. The dry lipid extract was resolved in chloroform and
added to silica gel plates (Merck 60, 10 £ 20 cm). The runner
solvent for the first run was hexane–diethyl ether–chloro-
form–acetic acid (21:6:3:1, by vol.). The plate was dried
under a hood at ambient temperature and ran again with
chloroform–methanol–water (65:25:4, by vol.). For position-
ing PC and PE ester bands, the proper oleates were ran in par-
allel in every plate. The bands were stained with
dichlorofluorescein, visualised under UV light and scrapped
for transmethylation.
Fatty acid methyl esters from individual fractions were
obtained by reaction with 3 M-HCl–methanol at 848C for
40 min according to the method of Lepage & Roy(18).
The quantification of fatty acid methyl esters from plasma
PL was performed by GC using a gas chromatograph
(HP5890 Series II; Hewlett Packard) equipped with a flame
ionisation detector. Chromatography was performed using a
60 m-long capillary column with a 0·32 mm internal diameter
and 0·20mm thickness and impregnated with SP-2330 FS
(Supelco). The injector and the detector were maintained at
250 and 2758C, respectively. N2 was used as the carrier gas
and the split ratio was 29:1. Fatty acid methyl esters were
identified by comparison of retention times with those of
known standards.
Analysis of fatty acid methyl esters from erythrocyte PE and
PC was performed by high-resolution capillary GLC (model
9001 GC; Finnigan/Tremetrics) with a split injection, an auto-
matic sampler (A200SE; CTC Analytic) and a flame ionisation
detector with a DB-23 cyanopropyl column of 60 m length
( J & W Scientific). The conditions during the analysis were
as follows: temperature of the injector at 808C for 0·1 min, tem-
perature increase by 1808C/min up to 2808C, temperature of
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the column area at 608C for 0·2 min, temperature increase by
408C/min up to 1808C, a 5 min hold period, temperature
increase by 1·58C/min up to 2008C, an 8·5 min hold period,
temperature increase by 408C/min up to 2408C and a 13 min
hold period. The constant linear velocity was 0·3 m/s (referred
to 1008C). For identification of sample peaks, we used two com-
mercially available fatty acid methyl ester calibration mixtures
(Supelco 37 FAME mix and NU-CKECK GLC reference 463)
containing the fatty acids measured in the present study.
Results are expressed as percentages by weight (wt%) of
total detected fatty acids with 14–24 C atoms.
Statistical analyses
The Kolmogorov–Smirnov or Shapiro–Wilk test was used
to test the normality of variables. Baseline characteristics
were compared among the intervention groups by using the
Kruskal–Wallis test for continuous data and the x 2 test for
ordinal data. A three-factor repeated-measures ANOVA with
the intervention group as the between-subject factor and
pregnancy time points (gestation week 20, gestation week
30 and delivery) as within-subject factors was performed to
compare the effects of supplementation with time. Differences
in cord blood fatty acid levels were assessed separately by
using ANOVA for normally distributed variables and the Krus-
kal–Wallis test for not normally distributed variables. If signifi-
cant effects were observed, multiple comparisons with
Bonferroni correction were performed.
Spearman’s correlations (r) were performed to determine
the correlations between plasma and erythrocyte relative
levels of fatty acids and between maternal fatty acid status at
delivery and neonatal fatty acid status at birth. P values less
than 0·05 were considered as significant.
Statistical analyses were performed using SPSS statistical
software (version 15.0; SPSS Institute).
Results
Sample description
Information regarding sample description, compliance, drop-
outs and baseline characteristics of study participants has
been reported previously(15). Briefly, 315 healthy women
with single pregnancies were recruited before the 20th week
of gestation. Of these, four did not fulfil the inclusion criteria
and were therefore excluded. Furthermore, forty-one women
did not complete the study; the main reasons for dropping out
were non-compliance, relocation and bad taste of the sup-
plement (FO: 10·4 %; FO þ 5-MTHF: 16·9 %; 5-MTHF: 16·6 %;
Table 1. Baseline characteristics of the study population after randomisation to intervention groups









n % n % n % n % P
Age (years) NS
Mean 31 31 30 31
SD 7 8 10 6
Parity NS
0 40 58·0 30 46·9 32 49·2 37 51·4
$1 29 42·0 34 53·1 33 50·8 35 48·6
Smoking 10 14·5 11 17·2 11 16·9 6 8·3 NS
Gestational age (weeks) NS
Mean 39 39 38 39
SD 2 2 3 2
Ethnicity (%) NS
Caucasian 69 100 63 98·4 64 98·5 70 97·2
Others 0 0 1 1·6 1 1·5 2 2·8
Residence area (%) NS
City area 32 46·4 29 45·3 32 49·2 37 51·4
Farm area 37 53·6 35 54·7 33 50·8 35 48·6
Gravidity risk (20 weeks) NS
No risk factor 19 27·5 20 31·2 18 27·7 28 38·9
$ 1 risk factor 50 72·5 44 68·8 47 72·3 44 61·1
Delivery risk NS
No risk factor 30 43·5 35 54·7 35 53·8 45 62·5
$ 1 risk factor 39 56·5 29 45·3 30 46·2 27 37·5
BMI (kg/m2)
20 weeks NS
Mean 26·0 25·2 25·2 24·9
SD 4·0 2·9 4·1 3·3
30 weeks NS
Mean 28·3 27·1 27·2 27·2
SD 4·4 3·1 4·4 3·6
FO, fish oil; 5-MTHF, 5-methyltetrahydrofolate.
* For continuous variables.
† For categorical variables.
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placebo: 10 %; P¼0·47). Compliance was good; 89·5 % of the
subjects in the second trimester of pregnancy and 87·4 %
in the third missed less than 5 d supplementation. Overall,
270 maternal blood samples could be drawn at the 30th
week of pregnancy and 243 at delivery. The available cord
blood samples for analyses were 220.
The baseline characteristics of the study participants are
shown in Table 1. Maternal clinical or sociodemographic
characteristics were similarly distributed in the four inter-
vention groups (P.0·05). There were no significant differ-
ences with respect to the course of pregnancy or delivery
complications between the groups (P.0·05). The habitual
basal dietary intake of energy, fatty acids and nutrients of
the participating mothers was similar in the four groups
throughout the study (P.0·05) except for the supplemen-
tation (Table S1, available online).
Fatty acid patterns in maternal plasma and erythrocyte
phospholipids during pregnancy and in umbilical plasma
and erythrocyte phospholipids at delivery
The mean values of fatty acids in maternal plasma and eryth-
rocyte PL during pregnancy and in umbilical plasma and
erythrocyte PL at delivery are shown in Tables 2–4.
DHA in maternal plasma PL and erythrocyte PC significantly
increased during the second half of pregnancy in the FO and
FO þ 5-MTHF groups (P,0·001) compared with the placebo
and 5-MTHF groups. DHA in maternal erythrocyte PE signifi-
cantly increased during the second half of pregnancy in all
Table 2. Relative fatty acid composition (wt%) of maternal and neonatal plasma phospholipids
(Mean values and standard deviations)
Week 20 Week 30 Delivery Newborn
Mean SD Mean SD Mean SD Mean SD
18 : 2n-6 FO* 21·22 2·79 20·50 2·95 19·98 3·01 8·02 1·91
FO þ 5-MTHF† 21·69A 2·43 20·71B 2·34 19·99B 2·92 7·86 1·21
5-MTHF‡ 21·55 2·53 21·38 2·18 20·82 2·39 7·41 1·02
Placebo§ 21·33 2·71 21·43 2·25 20·77 2·83 7·34 1·06
18 : 3n-3 FO 0·04 0·11 0·07 0·12 0·05 0·11 k k
FO þ 5-MTHF 0·04 0·11 0·04 0·11 0·06 0·13 k k
5-MTHF 0·02B 0·09 0·08A 0·13 0·11A 0·14 k k
Placebo 0·04 0·12 0·09 0·13 0·05 0·11 k k
20 : 4n-6 FO 10·41A 1·82 8·88B 1·47 8·93B 1·90 16·47a,b 2·33
FO þ 5-MTHF 10·40A 1·59 8·89B 1·27 8·94B 1·86 16·39b 2·04
5-MTHF 10·24A 2·12 9·20B 1·73 9·08B 1·77 17·38a 1·80
Placebo 10·18A 1·47 9·28B 1·56 9·46B 1·63 17·58a 1·88
22 : 6n-3 FO 4·43B 1·05 5·87a,A 1·61 5·69a,A 1·42 7·53a 1·69
FO þ 5-MTHF 4·54C 1·09 6·26a,A 1·17 5·84a,B 1·30 7·09a,b 1·83
5-MTHF 4·46 0·86 4·43b 0·81 4·31b 1·20 6·06c 1·62
Placebo 4·66A 1·14 4·19b,B 0·99 4·20b,B 1·24 6·53b,c 1·62
SSFA FO 43·75 2·32 43·71 1·27 44·19 1·21 48·95 1·71
FO þ 5-MTHF 43·76A,B 1·13 43·44B 1·22 44·14A 1·53 48·75 1·50
5-MTHF 43·77 1·25 43·68 1·05 43·89 1·20 49·30 1·55
Placebo 43·68 1·49 43·94 0·90 44·09 1·35 49·32 2·08
SMUFA FO 13·37B 2·49 14·46A,B 1·69 14·80a,b,A 1·73 12·58 2·21
FO þ 5-MTHF 13·20 2·34 14·21 1·68 14·49b 1·79 13·58 2·60
5-MTHF 13·62B 2·34 15·11A 1·63 15·31a,A 2·00 13·12 2·03
Placebo 13·49 2·18 14·71 1·60 14·98a,b 1·69 12·55 2·96
SPUFA FO 41·92A 3·20 41·09a,b,A 2·01 40·26B 1·82 37·61 2·35
FO þ 5-MTHF 42·50A 2·92 41·70a,A 1·70 40·71B 1·72 36·58 2·69
5-MTHF 41·93A 3·09 40·43b,B 1·50 40·06B 2·02 36·57 2·06
Placebo 42·21A 3·05 40·60b,A,B 1·60 40·31B 1·91 36·87 2·44
AA:DHA FO 2·47A 0·69 1·63b,B 0·57 1·67b,B 0·57 2·30b 0·65
FO þ 5-MTHF 2·41A 0·66 1·48b,B 0·39 1·61b,C 0·53 2·46b 0·71
5-MTHF 2·38A 0·65 2·14a,B 0·58 2·23a,A 0·66 3·10a 0·99
Placebo 2·32 0·65 2·35a 0·71 2·40a 0·69 2·85a 0·76
Sn-6:Sn-3 FO 6·85A 1·66 4·65b,B 1·55 4·90b,B 1·46 4·13c 0·99
FO þ 5-MTHF 6·78A 1·80 4·30b,C 1·12 4·73b,B 1·34 4·35b,c 1·26
5-MTHF 6·74 1·39 6·35a 1·40 6·40a 1·65 5·45a 1·65
Placebo 6·58 1·98 6·70a 1·87 6·86a 1·97 4·91a,b 1·30
FO, fish oil; 5-MTHF, 5-methyltetrahydrofoate; AA, arachidonic acid.
a,b,c Mean values within a column with unlike superscript letters were significantly different between the intervention groups (P,0·05).





kConcentration of 18 : 3n-3 in cord plasma phospholipids was too low to be detected.
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intervention groups. The increments observed in the FO-
supplemented groups (FO: 3·54 (SD 2·63) and FO þ 5-MTHF:
3·87 (SD 2·46)) were significantly higher than those observed
in the not FO-supplemented groups (5-MTHF: 1·44 (SD 1·75)
and placebo: 1·15 (SD 2·04)) (P,0·001). DHA levels significantly
increased between the 20th and 30th week of pregnancy in
plasma PL and erythrocyte PC but no increment was observed
between the 30th week of pregnancy and delivery. In contrast,
DHA levels in erythrocyte PE continued to significantly rise
between the 30th week of gestation and delivery (Figs. 1 and 2).
The degree of these changes was different in the various
lipid classes, with higher percentage changes in erythrocyte
PE (FO: þ67·8 % and FO þ 5-MTHF: þ71·8 %) and PC (FO:
þ77·6 % and FO þ 5-MTHF: 67·1 %) than in plasma PL (FO:
þ28·4 % and FO þ 5-MTHF: þ28·6 %) (P,0·001).
No differences in maternal or fetal fatty acid levels in both
plasma or erythrocyte PL were observed between the
groups supplemented with 5-MTHF and the groups that did
not receive 5-MTHF supplements (Tables 2–4).
Correlations between fatty acid relative levels (percentage
of total fatty acids) in plasma and erythrocyte
phospholipids
Significant correlations were observed between DHA levels in
maternal plasma and their levels in erythrocytes (PC and PE).
Correlation coefficients in the FO-supplemented groups did
not differ from those observed in the not FO-supplemented
groups (P.0·05; Figs. 1 and 2; Table S2, available online).
DHA levels in cord plasma significantly correlated with their
levels in cord erythrocytes. Correlation coefficients for the
Table 3. Relative fatty acid composition (wt%) of maternal and neonatal erythrocyte phosphatidylcholine
(Mean values and standard deviations)
Week 20 Week 30 Delivery Newborn
Mean SD Mean SD Mean SD Mean SD
18 : 2n-6 FO* 15·67 2·68 15·35 2·86 15·70 2·72 6·88 2·32
FO þ 5-MTHF† 15·62 2·60 15·43 2·74 15·48 2·56 6·72 1·17
5-MTHF‡ 15·55 2·08 14·78 2·72 15·06 2·77 6·52 1·28
Placebo§ 15·35 2·79 15·51 2·48 15·65 2·63 5·95 1·01
18 : 3n-3 FO 0·11 0·09 0·15 0·13 0·16 0·13 0·04 0·04
FO þ 5-MTHF 0·13 0·10 0·12 0·06 0·14 0·09 0·08 0·09
5-MTHF 0·18 0·14 0·17 0·16 0·17 0·12 0·11 0·24
Placebo 0·14 0·13 0·14 0·11 0·13 0·10 0·04 0·04
20 : 4n-6 FO 6·64 3·13 7·07b 2·57 7·02 2·56 12·11 3·43
FO þ 5-MTHF 7·34 2·41 6·73b 2·48 7·37 2·17 12·62 2·51
5-MTHF 7·40 2·21 7·50b 2·58 7·93 2·43 11·51 3·93
Placebo 7·56B 2·41 8·69a,A 2·20 8·13A,B 2·57 12·88 3·97
22 : 6n-3 FO 1·92B 1·00 2·95A 1·57 3·41A 1·70 3·97a 1·62
FO þ 5-MTHF 2·22B 1·13 3·19A 1·37 3·71A 1·42 3·96a 1·47
5-MTHF 2·41 1·02 2·43 1·12 2·59 1·11 2·71b 1·27
Placebo 2·41 1·15 2·75 1·20 2·51 0·94 2·82b 1·31
SSFA FO 53·92A 4·12 52·95A,B 3·46 52·62B 3·54 54·98 4·45
FO þ 5-MTHF 53·46 4·81 52·53 3·28 52·02 3·46 54·73 3·78
5-MTHF 52·38 2·90 52·28 2·95 51·75 3·19 55·68 4·36
Placebo 52·99 3·89 51·82 3·57 51·95 3·12 55·92 4·52
SMUFA FO 16·18 2·26 15·70 2·15 15·40 2·17 13·95a,b 2·22
FO þ 5-MTHF 15·41A,B 2·32 15·92A 2·49 15·26B 2·02 13·54b 1·81
5-MTHF 16·03 1·67 16·45 2·25 15·94 2·14 14·91a 2·16
Placebo 15·52 2·13 14·84 1·47 15·43 1·82 14·20a,b 2·32
SPUFA FO 27·55B 4·66 29·03A,B 4·38 29·83A 4·46 27·88 5·30
FO þ 5-MTHF 28·69 4·02 29·19 4·43 30·44 3·54 28·32 4·04
5-MTHF 29·22 3·43 28·69 4·96 29·84 4·19 25·63 5·52
Placebo 29·09B 4·31 31·12A 3·48 30·27A,B 3·61 26·19 5·64
AA:DHA FO 4·01A 1·76 2·84b,c,B 1·14 2·36b,C 0·82 3·44b 1·44
FO þ 5-MTHF 3·94A 1·85 2·47c,B 1·61 2·17b,C 0·76 3·47b 0·96
5-MTHF 3·48 1·30 3·53a,b 1·30 3·44a 1·24 4·75a 1·62
Placebo 3·76 1·88 3·71a 1·58 3·59a 1·37 5·14a 1·77
Sn-6:Sn-3 FO 12·16A 7·88 7·93a,b,B 4·47 6·94b,c,B 4·02 5·43b 2·28
FO þ 5-MTHF 10·01A 6·17 7·27b,A 6·76 6·00c,B 2·98 5·18b 1·44
5-MTHF 8·62B 4·13 9·68a,A 9·15 8·10a,b,B 3·89 7·09a 2·60
Placebo 8·70 4·57 8·77a,b 6·67 9·00a 6·59 7·00a 2·50
FO, fish oil; 5-MTHF, 5-methyltetrahydrofoate; AA, arachidonic acid.
a,b,c Mean values within a column with unlike superscript letters were significantly different between the intervention groups (P,0·05).
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association were r 0·354 (P,0·001) and r 0·348 (P,0·001) for
erythrocyte PC and PE, respectively.
Correlations between maternal and neonatal fatty acid
relative levels in plasma and erythrocyte phospholipids
at delivery
DHA and arachidonic acid (AA) percentage levels in cord
blood correlated significantly with fatty acid levels in maternal
blood at delivery in both plasma and erythrocyte PL (Fig. 3).
Correlation coefficients were higher in erythrocyte PE com-
pared with those observed in plasma or erythrocyte PC
(P,0·05; Table S3, available online).
Discussion
It is well known from interventional studies that mothers con-
suming n-3 LC-PUFA supplements have higher n-3 LC-PUFA
levels in both plasma and erythrocytes during pregnancy
and at delivery(3,7–9,15,19). Higher levels of n-3 LC-PUFA have
also been reported in umbilical cord plasma and erythrocyte
PL in supplemented mothers(15,19,20). Furthermore, DHA
levels in cord blood plasma and erythrocytes have been
demonstrated to correlate with maternal blood DHA
levels(3,6,21,22). In agreement with previous interventional
studies, FO(3,7–9,15,19) supplementation in the second half of
pregnancy significantly increased DHA levels in maternal
and umbilical plasma and erythrocyte PL. Supplementation
did not significantly modify AA levels in umbilical erythrocyte
membrane PL but AA levels in umbilical plasma PL were sig-
nificantly lower in the FO-supplemented groups. Supplemen-
tation with 500 mg/d of DHA in populations with a mean daily
DHA intake above the recommended 200 mg/d(1,23) may
lower AA in the fetus. The supplementation with a AA–DHA
blend has proven to increase DHA levels without decreasing
Table 4. Relative fatty acid composition (wt%) of maternal and neonatal erythrocyte phosphatidylethanolamine
(Mean values and standard deviations)
Week 20 Week 30 Delivery Newborn
Mean SD Mean SD Mean SD Mean SD
18 : 2n-6 FO* 6·22A 1·17 5·75b,B 1·09 5·99A,B 1·37 2·74 0·90
FO þ 5-MTHF† 6·37A 1·13 5·86a,b,B 0·93 5·90B 0·94 2·78 0·67
5-MTHF‡ 6·04 0·98 6·12a 0·93 6·21 1·05 2·72 0·60
Placebo§ 5·97 0·95 6·15a,b 0·90 6·12 1·13 2·60 0·83
18 : 3n-3 FO 0·21 0·19 0·19 0·16 0·21 0·20 0·14 0·18
FO þ 5-MTHF 0·28 0·26 0·26 0·20 0·24 0·23 0·21 0·30
5-MTHF 0·23 0·24 0·25 0·24 0·22 0·16 0·20 0·24
Placebo 0·20 0·17 0·22 0·21 0·23 0·21 0·12 0·12
20 : 4n-6 FO 20·36A 5·34 19·20a,b,A,B 4·14 19·19a,b,B 4·23 24·30 6·02
FO þ 5-MTHF 19·49A 4·86 18·04a,b,B 4·04 18·13b,B 3·32 23·85 4·18
5-MTHF 18·82A 4·97 17·31b,B 4·34 18·97a,b,A,B 3·59 24·35 5·14
Placebo 19·65 4·83 19·64a 4·54 20·09a 3·66 25·19 5·89
22 : 6n-3 FO 5·22C 1·76 7·20a,b,B 2·33 8·76a,A 2·65 8·64a,b 2·41
FO þ 5-MTHF 5·47C 1·80 7·88a,B 2·73 9·40a,A 2·65 9·39a 2·53
5-MTHF 5·43B 2·15 5·60c,B 2·12 6·89b,A 2·21 7·76b 1·90
Placebo 5·42B 1·99 5·94b,c,A,B 1·91 6·54b,A 1·81 7·57b 1·91
SSFA FO 36·43 5·27 36·83 5·15 35·15 4·11 39·04 6·06
FO þ 5-MTHF 37·34A 6·36 35·91A,B 5·04 34·56B 3·95 38·35 4·55
5-MTHF 37·02A,B 5·36 38·07A 5·67 35·35B 4·62 38·95 5·39
Placebo 37·56 6·12 36·18 4·74 35·42 3·94 39·31 6·11
SMUFA FO 24·15 2·99 23·36 2·53 23·20 2·19 17·62 2·35
FO þ 5-MTHF 23·72 2·87 24·62 3·29 23·98 3·02 17·62 2·51
5-MTHF 24·76 3·07 25·02 3·74 24·61 3·06 17·87 2·25
Placebo 23·87 3·02 24·48 2·99 24·19 2·56 17·61 2·04
SPUFA FO 36·92 7·09 37·51 6·27 39·55 5·56 41·12 7·44
FO þ 5-MTHF 36·46B 7·13 37·23A,B 7·39 39·31A 5·69 41·69 5·68
5-MTHF 35·54A,B 7·37 34·16B 6·81 37·68A 5·65 40·50 6·56
Placebo 36·02 7·00 37·03 6·69 38·14 5·02 40·49 7·31
AA:DHA FO 4·17A 1·23 2·90b,B 1·02 2·37b,C 0·80 2·95a,b 0·79
FO þ 5-MTHF 3·75A 0·88 2·47b,B 0·63 2·04b,C 0·56 2·73b 0·87
5-MTHF 3·83A 1·17 3·38a,A 1·03 2·95a,B 0·81 3·26a 0·81
Placebo 3·96A 1·17 3·51a,B 0·84 3·23a,B 0·87 3·45a 0·82
Sn-6:Sn-3 FO 3·65A 0·85 2·70b,B 0·75 2·34b,C 0·67 2·95b,c 0·75
FO þ 5-MTHF 3·46A 0·83 2·45b,B 0·61 2·06b,C 0·52 2·72c 0·65
5-MTHF 3·49A 1·04 3·17a,A 0·88 2·79a,B 0·71 3·2a,b 0·73
Placebo 3·49A 0·85 3·27a,A,B 0·79 3·04a,B 0·77 3·40a 0·67
FO, fish oil; 5-MTHF, 5-methyltetrahydrofoate; AA, arachidonic acid.
a,b,c Mean values within a column with unlike superscript letters were significantly different between the intervention groups (P,0·05).
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the levels of AA and may be a better way of avoiding the AA
fall following n-3 LC-PUFA supplementation(9).
Human fatty acid status depends only partially on dietary
intake. Genetic and metabolic factors, as well as lifestyle
determinants, may affect fatty acid concentrations in human
tissues. Furthermore, pregnancy may modify plasma and
erythrocyte fatty acid concentrations as a result of the occur-
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Fig. 1. Scattered data graph of DHA percentage concentrations in plasma and erythrocyte membrane phosphatidylcholine (PC) during the course of pregnancy in
(a) the fish oil (FO)-supplemented (FO and FO þ 5-methyltetrehydrofolate) and (b) not supplemented (placebo and 5-methyltetrahydrofolate) groups. (a) Week 20:
R 0·154, P¼0·152; week 30: R 0·275, P¼0·005; delivery: R 0·485, P,0·001. (b) Week 20: R 0·234, P¼0·031; week 30: R 0·372, P¼0·001; delivery: R 0·467,
P,0·001. PL, phospholipid; DHA PC, DHA levels in erythrocyte membrane PC.
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Fig. 2. Scattered data graph of DHA relative concentrations in plasma and erythrocyte membrane phosphatidylethanolamine (PE) during the course of pregnancy
in (a) the fish oil (FO)-supplemented (FO and FO þ 5-methyltetrahydrofolate) and (b) not supplemented (placebo and 5-methyltetrahydrofolate) groups.
(a) Week 20: R 0·148, P¼0·133; week 30: R 0·252, P¼0·008; delivery: R 0·473, P,0·001. (b) Week 20: R 0·219, P¼0·028; week 30: R 0·276, P¼0·008; delivery:
R 0·292, P¼0·007. PL, phospholipid; DHA PE, DHA levels in erythrocyte membrane PE.


















Downloaded from https:/www.cambridge.org/core. IP address: 138.246.2.185, on 03 Mar 2017 at 15:54:30, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
in order to establish the most confident compartment for the
assessment of the LC-PUFA status of individuals. A revised
meta-analysis of intervention studies concluded that both
plasma and erythrocyte PL appear to be good markers for
DHA status in humans, but special consideration should be
given to particular population subgroups(24). Only a few
studies have evaluated the influence of n-3 PUFA supplements
during the course of pregnancy in both erythrocytes and
plasma in the same population(8,9).
Studies on the kinetics of fatty acid incorporation into
plasma PL and erythrocytes after DHA supplementation have
shown a dose-dependent rapid increase of DHA in plasma
PL with a subsequent steady-state concentration 1 month
after the start of supplementation. Erythrocytes follow a simi-
lar pattern but it takes 4–6 months to reach equilibrium(25–27).
In addition, most of the PE in erythrocyte membranes is
located in the inner layer, whereas PC is in the outer layer
and can therefore interact more easily with circulating
plasma lipids. Thus, PC reflects more directly the fatty acid
composition of plasma PL, whereas the fatty acid composition
of PE appears to be more dependent on a selective incorpor-
ation of LC-PUFA into PE. A study on DHA supplementation in
healthy adult vegetarians showed strong correlations between















































































































































































20000 4000 6000 8000
8000
10000 4000 6000 8000 10000 12 000 14 000
Maternal 22 : 6n-3 in plasma PL
Maternal 22 : 6n-3 in erythrocyte PC Maternal 20 : 4n-6 in erythrocyte PC
Maternal 22 : 6n-3 in erythrocyte PE Maternal 20 : 4n-6 in erythrocyte PE
Maternal 20 : 4n-6 in plasma PL
Fig. 3. Linear regression models for the relationship between maternal (a, c, e) DHA and (b, d, f) arachidonic acid levels expressed as a percentage of total fatty
acids (wt%) at delivery and their relative levels in cord plasma and erythrocyte membrane (c, d) phosphatidylcholine (PC) and (e, f) phosphatidylethanolamine
(PE). (a) R 0·522, P,0·001; (b) R 0·559, P,0·001; (c) R 0·516, P,0·001; (d) R 0·404, P,0·001; (e) R 0·686, P,0·001; (f) R 0·690, P,0·001. PL, phospholipid.
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erythrocyte PE and plasma PL fatty acid changes were less clo-
sely related(28). After the first 10 weeks of supplementation in
the present study, DHA levels in maternal plasma and erythro-
cyte PC may have risen to their steady-state levels and conse-
quently do not continue to increase in the last weeks of
pregnancy. DHA in erythrocyte PE may need longer to
reach the steady-state concentration and therefore continues
to increase until delivery. Given the slow turnover of fatty
acids in cell membranes, erythrocyte PL may be a more
reliable measure of long-term fatty acid intake, whereas
plasma PL appear more sensitive to short-term changes in
the intake of LC-PUFA and may be more suitable to monitor
the fatty acid status of individuals in intervention studies.
Both plasma and erythrocyte fatty acids appear adequate to
assess the fatty acid status in pregnant women and their neo-
nates but the type of study is a major consideration when
determining which body compartment reflects a better
measure of fatty acid status.
It should be taken into account that studies on the kinetics
of incorporation of fatty acids in plasma and erythrocyte PL
have not been conducted in pregnant women. Most studies
conducted in pregnancy have reported a similar evolution pat-
tern of fatty acids in both plasma and erythrocyte and reported
the positive correlations between maternal plasma and eryth-
rocyte fatty acid levels and fatty acid changes throughout
gestation(21,22,29), which is consistent with the present results.
In general, changes observed in erythrocyte membrane PL
mirror those occurring in plasma PL but we observed that
the degrees of DHA percentage changes were different in
the various lipid fractions. Geppert et al.(28) in their study in
healthy adult vegetarians reported that relative changes of
DHA 8 weeks after supplementation were greater in plasma
and erythrocyte PC than in erythrocyte total lipids and eryth-
rocyte PE, which contrast with the present finding of greater
changes in erythrocyte PE and PC compared with plasma
PL. Vlaardingerbroek & Hornstra(22) observed in their study
that the amount of most fatty acids continued to increase in
erythrocytes after 32 week of pregnancy while the amounts
in plasma hardly increased or even decreased, which is con-
sistent with the present findings. These authors have
suggested that the increment observed in erythrocyte PL
could be explained by the replacement during pregnancy of
erythrocyte PL classes with one ester-linked fatty acid moiety
by PL classes carrying two ester-linked fatty acids, such as
PC and PE(30). As a result, plasma lipids could be more readily
adsorbed to the erythrocyte membrane, which could explain
the higher percentage increase of DHA in erythrocyte PC
and PE. There is evidence suggesting that erythrocytes play
an important role in the transport of DHA into the fetus(31);
the increment of PE and PC in erythrocyte membrane may
be an adaptation mechanism during pregnancy to increase
the transfer of LC-PUFA. However, further research is
needed to elucidate the mechanism of how erythrocytes
provide LC-PUFA to the fetus.
We observed positive significant correlations between
plasma and erythrocyte DHA levels, which is consistent with
previously reported data(21,22,29). Our correlation coefficients
were considerably lower than those reported in non-pregnant
individuals(28). Fatty acids bind to TAG in high proportion
during pregnancy(32), and the fact that we did not consider
the LC-PUFA fraction bound to TAG in the present study
could explain our lower correlation coefficients.
Correlation coefficients between maternal and cord fatty
acid relative levels at delivery were significantly higher in
erythrocyte PE compared with the correlation coefficients in
plasma PL. Plasma levels of lipoproteins in cord serum are
low, with HDL being the major lipoprotein and LDL and
VLDL present in low and very low concentrations(33,34).
Thus, in agreement with previously reported data(31), it
could be hypothesised that erythrocyte membrane PL are
important carriers of LC-PUFA in fetal blood, which could
explain the higher correlation coefficients between maternal
and fetal fatty acid percentage levels in erythrocyte membrane
PL. These results suggest that erythrocyte PL seem to be a
more reliable biomarker for the prediction of fetal/neonatal
fatty acid status on the basis of maternal fatty acid levels.
Both plasma and erythrocyte fatty acid levels seem to be
suitable to assess maternal fatty acid status. More information
on the physiological changes taking place in the erythrocyte
membrane during gestation, as well as further knowledge
about fetal metabolism and the kinetics of fatty acid accretion
in fetal tissues, is needed. Nevertheless, fatty acid levels
in erythrocyte PL seem to be a more reliable biomarker
compared with those in plasma PL to predict the fetal/
neonatal fatty acid status on the basis of maternal blood
fatty acid levels.
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